Merck's HPV Vaccine Produces Stronger Immune Response in Girls, Boys Than Women, Study

... Pharmaceutical company Merck on Thursday at a meeting of the European Society of Pediatric Infectious Diseases in Valencia, Spain, announced that a study of the company's experimental vaccine targeting the four strains of the sexually transmitted disease human papillomavirus that are most likely to cause cervical cancer or genital warts showed that the vaccine produces a stronger immune response in male and female adolescents ages 10 to 15 than in young women ages 16 to 23,... click link for more info. ...